

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
1	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Purchase of goods or services		102	Amount as approved by the Audit Committee.			102	-	-	-		-	-	-	-	-	-	-	
2	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Purchase of goods or services		70	Amount as approved by the Audit Committee.			70	-	-	-		-	-	-	-	-	-	-	
3	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Purchase of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-	
4	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
5	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Purchase of goods or services		2	Amount as approved by the Audit Committee.			2	-	-	-		-	-	-	-	-	-	-	
6	Zydus Lifesciences Limited	Zydus Healthcare (USA) LLC	Subsidiary Company	Purchase of goods or services		100	Amount as approved by the Audit Committee.			100	-	-	-		-	-	-	-	-	-	-	
7	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
8	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Purchase of goods or services		25	Amount as approved by the Audit Committee.			25	-	-	-		-	-	-	-	-	-	-	
9	Zydus Lifesciences Limited	Sterling Biotech Limited	Joint Ventures	Purchase of goods or services		28	Amount as approved by the Audit Committee.			28	-	-	-		-	-	-	-	-	-	-	
10	Zydus Lifesciences Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		5	Amount as approved by the Audit Committee.			5	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
11	Zydus Lifesciences Limited	Oneiro Chemicals Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		436	Amount as approved by the Audit Committee.			436	-	-	-		-	-	-	-	-	-	-	
12	Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Purchase of fixed assets		24	Amount as approved by the Audit Committee.			24	-	-	-		-	-	-	-	-	-	-	
13	Zydus Lifesciences Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of fixed assets		18	Amount as approved by the Audit Committee.			18	-	-	-		-	-	-	-	-	-	-	
14	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
15	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Purchase of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-	
16	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Purchase of goods or services		242	Amount as approved by the Audit Committee.			242	-	-	-		-	-	-	-	-	-	-	
17	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Purchase of goods or services		31	Amount as approved by the Audit Committee.			31	-	-	-		-	-	-	-	-	-	-	
18	Zydus Lifesciences Limited	Zydus Medtech France SAS	Subsidiary Company	Sale of goods or services		30	Amount as approved by the Audit Committee.			30	-	-	-		-	-	-	-	-	-	-	
19	Zydus Lifesciences Limited	Zydus Medtech France SAS	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	30	-		-	-	-	-	-	-	-	
20	Zydus Lifesciences Limited	Vitely Corp Pvt Ltd (Formerly Known Vitely Bio LLP)	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		11	Amount as approved by the Audit Committee.			11	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
21	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
22	Zydus Lifesciences Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		2	Amount as approved by the Audit Committee.			2	-	-	-		-	-	-	-	-	-	-	
23	Zydus Lifesciences Limited	Mukesh M. Patel & Co., Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		5	Amount as approved by the Audit Committee.			5	-	-	-		-	-	-	-	-	-	-	
24	Zydus Lifesciences Limited	International Tax & Investment Consultants-Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		3	Amount as approved by the Audit Committee.			3	-	-	-		-	-	-	-	-	-	-	
25	Zydus Lifesciences Limited	TUV India Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
26	Zydus Lifesciences Limited	Apollo Healthco Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	0	-		-	-	-	-	-	-	-	
27	Zydus Lifesciences Limited	Apollo Healthco Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		2	Amount as approved by the Audit Committee.			2	-	-	-		-	-	-	-	-	-	-	
28	Zydus Lifesciences Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		74	Amount as approved by the Audit Committee.			74	-	-	-		-	-	-	-	-	-	-	
29	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	838	Amount as approved by the Audit Committee.			838	-	-	-		-	-	-	-	-	-	-	
30	Zydus Lifesciences Limited	Zydus Healthcare (USA) LLC	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	18	Amount as approved by the Audit Committee.			18	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
31	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	18	Amount as approved by the Audit Committee.			18	-	-	-		-	-	-	-	-	-	-	
32	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	4	Amount as approved by the Audit Committee.			4	-	-	-		-	-	-	-	-	-	-	
33	Zydus Lifesciences Limited	Zydus France, SAS	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	129	Amount as approved by the Audit Committee.			129	-	-	-		-	-	-	-	-	-	-	
34	Zydus Lifesciences Limited	Laboratorios Combi S.L.	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	87	Amount as approved by the Audit Committee.			87	-	-	-		-	-	-	-	-	-	-	
35	Zydus Lifesciences Limited	Zydus Lanka (Private) Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
36	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	4	Amount as approved by the Audit Committee.			4	-	-	-		-	-	-	-	-	-	-	
37	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	73	Amount as approved by the Audit Committee.			73	-	-	-		-	-	-	-	-	-	-	
38	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Reimbursement of Expenses paid	0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
39	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Any other transaction	Reimbursement of Expenses paid	2	Amount as approved by the Audit Committee.			2	-	-	-		-	-	-	-	-	-	-	
40	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Sale of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
41	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Sale of goods or services		393	Amount as approved by the Audit Committee.			393	-	-	-		-	-	-	-	-	-	-	
42	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Sale of goods or services		511	Amount as approved by the Audit Committee.			511	-	-	-		-	-	-	-	-	-	-	
43	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Sale of goods or services		27,247	Amount as approved by the Audit Committee.			27,247	-	-	-		-	-	-	-	-	-	-	
44	Zydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Sale of goods or services		2,292	Amount as approved by the Audit Committee.			2,292	-	-	-		-	-	-	-	-	-	-	
45	Zydus Lifesciences Limited	Zydus Healthcare Philippines Inc.	Subsidiary Company	Sale of goods or services		466	Amount as approved by the Audit Committee.			466	-	-	-		-	-	-	-	-	-	-	
46	Zydus Lifesciences Limited	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Sale of goods or services		76	Amount as approved by the Audit Committee.			76	-	-	-		-	-	-	-	-	-	-	
47	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Sale of goods or services		442	Amount as approved by the Audit Committee.			442	-	-	-		-	-	-	-	-	-	-	
48	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Sale of goods or services		828	Amount as approved by the Audit Committee.			828	-	-	-		-	-	-	-	-	-	-	
49	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Sale of goods or services		551	Amount as approved by the Audit Committee.			551	-	-	-		-	-	-	-	-	-	-	
50	Zydus Lifesciences Limited	Zydus France, SAS	Subsidiary Company	Sale of goods or services		557	Amount as approved by the Audit Committee.			557	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
51	Zydus Lifesciences Limited	Laboratorios Combix S.L.	Subsidiary Company	Sale of goods or services		306	Amount as approved by the Audit Committee.			306	-	-	-		-	-	-	-	-	-	-	
52	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Sale of goods or services		255	Amount as approved by the Audit Committee.			255	-	-	-		-	-	-	-	-	-	-	
53	Zydus Lifesciences Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Sale of goods or services		1,522	Amount as approved by the Audit Committee.			1,522	-	-	-		-	-	-	-	-	-	-	
54	Zydus Lifesciences Limited	Zydus Takeda Healthcare Private Limited	Joint Ventures	Sale of goods or services		104	Amount as approved by the Audit Committee.			104	-	-	-		-	-	-	-	-	-	-	
55	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Sale of goods or services		12	Amount as approved by the Audit Committee.			12	-	-	-		-	-	-	-	-	-	-	
56	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Sale of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-	
57	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Loan		-	N.A.			1,000	-	-	-		-	-	-	-	-	-	-	
58	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Purchase of fixed assets		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
59	Zydus Lifesciences Limited	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Sale of goods or services		11	Amount as approved by the Audit Committee.			11	-	-	-		-	-	-	-	-	-	-	
60	Zydus Lifesciences Limited	Zydus Wellness Limited	Subsidiary Company	Sale of goods or services		4	Amount as approved by the Audit Committee.			4	-	-	-		-	-	-	-	-	-	-	
61	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of goods or services		11	Amount as approved by the Audit Committee.			11	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
62	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Sale of goods or services		3	Amount as approved by the Audit Committee.			3	-	-	-		-	-	-	-	-	-	-	
63	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Sale of goods or services		5	Amount as approved by the Audit Committee.			5	-	-	-		-	-	-	-	-	-	-	
64	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Sale of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-	
65	Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Sale of goods or services		18	Amount as approved by the Audit Committee.			18	-	-	-		-	-	-	-	-	-	-	
66	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Sale of goods or services		178	Amount as approved by the Audit Committee.			178	-	-	-		-	-	-	-	-	-	-	
67	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Sale of goods or services		19	Amount as approved by the Audit Committee.			19	-	-	-		-	-	-	-	-	-	-	
68	Zydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Sale of goods or services		5	Amount as approved by the Audit Committee.			5	-	-	-		-	-	-	-	-	-	-	
69	Zydus Lifesciences Limited	Zydus Therapeutics INC	Subsidiary Company	Sale of goods or services		37	Amount as approved by the Audit Committee.			37	-	-	-		-	-	-	-	-	-	-	
70	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Sale of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-	
71	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Sale of goods or services		30	Amount as approved by the Audit Committee.			30	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
72	Zydus Lifesciences Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Sale of goods or services		115	Amount as approved by the Audit Committee.			115	-	-	-		-	-	-	-	-	-	-	
73	Zydus Lifesciences Limited	Zydus Medtech Private Limited	Subsidiary Company	Investment		-	N.A.			210	1,395	1,605	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose	
74	Zydus Lifesciences Limited	Zydus Medtech Private Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	2	2	-		-	-	-	-	-	-	-	
75	Zydus Lifesciences Limited	Zydus Medtech Private Limited	Subsidiary Company	Sale of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
76	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	48	Amount as approved by the Audit Committee.			48	-	-	-		-	-	-	-	-	-	-	
77	Zydus Lifesciences Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Interest received		-	N.A.			101	-	-	-		-	-	-	-	-	-	-	
78	Zydus Lifesciences Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Loan		-	N.A.			1,292	-	-	-		-	-	Loans	6 Month SOFR + 240 BPS	5 Year	Unsecured	Business Purpose	
79	Zydus Lifesciences Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	1,715	3,214	-		-	-	-	-	-	-	-	
80	Zydus Lifesciences Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	160	Amount as approved by the Audit Committee.			160	-	-	-		-	-	-	-	-	-	-	
81	Zydus Lifesciences Limited	Zydus Wellness Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-	
82	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	10	Amount as approved by the Audit Committee.			10	-	-	-		-	-	-	-	-	-	-	
83	Zydus Lifesciences Limited	Mr. Pankaj R. Patel	Key Managerial Personnel	Any other transaction	Director Sitting Fees	-	N.A.			1	-	-	-		-	-	-	-	-	-	-	
84	Zydus Lifesciences Limited	Dr. Sharvil P. Patel	Key Managerial Personnel	Remuneration		-	N.A.			180	-	-	-		-	-	-	-	-	-	-	
85	Zydus Lifesciences Limited	Mr. Ganesh N. Nayak	Key Managerial Personnel	Remuneration		-	N.A.			28	-	-	-		-	-	-	-	-	-	-	
86	Zydus Lifesciences Limited	Mr. Nitin D. Parekh	Key Managerial Personnel	Remuneration		-	N.A.			37	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
87	Zydus Lifesciences Limited	Mr. Tushar D. Shroff	Key Managerial Personnel	Remuneration		-	N.A.			3	-	-	-		-	-	-	-	-	-	-	
88	Zydus Lifesciences Limited	Mr. Dhaval N. Soni	Key Managerial Personnel	Remuneration		-	N.A.			3	-	-	-		-	-	-	-	-	-	-	
89	Zydus Lifesciences Limited	Dialforhealth Unity Limited	Subsidiary Company	Interest received		-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
90	Zydus Lifesciences Limited	Zydus International Private Limited	Subsidiary Company	Interest received		-	N.A.			305	-	-	-		-	-	-	-	-	-	-	
91	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Interest received		-	N.A.			230	-	-	-		-	-	-	-	-	-	-	
92	Zydus Lifesciences Limited	Sentynl Therapeutics Inc.	Subsidiary Company	Interest received		-	N.A.			314	-	-	-		-	-	-	-	-	-	-	
93	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Interest received		-	N.A.			82	-	-	-		-	-	-	-	-	-	-	
94	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Sale of goods or services		50	Amount as approved by the Audit Committee.			50	-	-	-		-	-	-	-	-	-	-	
95	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Interest received		-	N.A.			43	-	-	-		-	-	-	-	-	-	-	
96	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Interest paid		-	N.A.			34	-	-	-		-	-	-	-	-	-	-	
97	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Interest paid		-	N.A.			373	-	-	-		-	-	-	-	-	-	-	
98	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Interest paid		-	N.A.			1,254	-	-	-		-	-	-	-	-	-	-	
99	Zydus Lifesciences Limited	Zydus Takeda Healthcare Private Limited	Joint Ventures	Dividend received		-	N.A.			200	-	-	-		-	-	-	-	-	-	-	
100	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Dividend received		-	N.A.			200	-	-	-		-	-	-	-	-	-	-	
101	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Loan		-	N.A.			2,138	-	-	-		-	-	Loans	6 Month SONIA + 190 BPS	5 Year	Unsecured	Business Purpose	
102	Zydus Lifesciences Limited	LM Manufacturing India Private Limited	Subsidiary Company	Interest received		-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
103	Zydus Lifesciences Limited	LM Manufacturing India Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	4	4	-		-	-	-	-	-	-	-	
104	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Investment		-	N.A.			2,250	7,600	9,850	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose	
105	Zydus Lifesciences Limited	Zydus Pharmaceuticals Canada Inc.	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	4	Amount as approved by the Audit Committee.			4	-	-	-		-	-	-	-	-	-	-	
106	Zydus Lifesciences Limited	Zydus Pharmaceuticals Canada Inc.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	1	-		-	-	-	-	-	-	-	
107	Zydus Lifesciences Limited	Zynext Ventures Pte. Ltd.	Subsidiary Company	Investment		-	N.A.			-	797	-	-		-	-	-	-	-	-	-	
108	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Loan		-	N.A.			13,684	-	-	-		-	-	-	-	-	-	-	
109	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Loan		-	N.A.			5,447	-	-	-		-	-	-	-	-	-	-	
110	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Loan		-	N.A.			7,101	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
111	Zydus Lifesciences Limited	Cadila Healthcare Ltd. Managerial Cadre EPF	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.			385	-	-	-		-	-	-	-	-	-	-	
112	Zydus Lifesciences Limited	Cadila Healthcare Limited Employees Group Gratuity Scheme	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.			16	-	-	-		-	-	-	-	-	-	-	
113	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.			-	11,451	11,778	-		-	-	-	-	-	-	-	
114	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.			-	42,347	39,280	-		-	-	-	-	-	-	-	
115	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.			-	1,035	1,000	-		-	-	-	-	-	-	-	
116	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	442	258	-		-	-	-	-	-	-	-	
117	Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	11	29	-		-	-	-	-	-	-	-	
118	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	379	244	-		-	-	-	-	-	-	-	
119	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	650	911	-		-	-	-	-	-	-	-	
120	Zydus Lifesciences Limited	Zydus Healthcare (USA) LLC	Subsidiary Company	Investment		-	N.A.			221	-	221	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose	
121	Zydus Lifesciences Limited	Zydus Healthcare (USA) LLC	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	62	41	-		-	-	-	-	-	-	-	
122	Zydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	75	84	-		-	-	-	-	-	-	-	
123	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	291	311	-		-	-	-	-	-	-	-	
124	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	60	69	-		-	-	-	-	-	-	-	
125	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	79	88	-		-	-	-	-	-	-	-	
126	Zydus Lifesciences Limited	Zydus France, SAS	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	249	318	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
127	Zydus Lifesciences Limited	Zydus Lanka (Private) Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	2	0	-		-	-	-	-	-	-	-	
128	Zydus Lifesciences Limited	Zydus Lanka (Private) Limited	Subsidiary Company	Sale of goods or services		3	Amount as approved by the Audit Committee.			3	-	-	-		-	-	-	-	-	-	-	
129	Zydus Lifesciences Limited	Zydus Lanka (Private) Limited	Subsidiary Company	Sale of goods or services		2	Amount as approved by the Audit Committee.			2	-	-	-		-	-	-	-	-	-	-	
130	Zydus Lifesciences Limited	Zydus Lanka (Private) Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	0	5	-		-	-	-	-	-	-	-	
131	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	13	13	-		-	-	-	-	-	-	-	
132	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	15	65	-		-	-	-	-	-	-	-	
133	Zydus Lifesciences Limited	Sterling Biotech Limited	Joint Ventures	Any other transaction	Capital Advances	-	N.A.			250	-	-	-		-	-	-	-	-	-	-	
134	Zydus Lifesciences Limited	Sterling Biotech Limited	Joint Ventures	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	7	14	-		-	-	-	-	-	-	-	
135	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	2	-	-		-	-	-	-	-	-	-	
136	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	0	0	-		-	-	-	-	-	-	-	
137	Zydus Lifesciences Limited	Vitely Corp Pvt Ltd (Formerly Known Vitely Bio LLP)	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	0	4	-		-	-	-	-	-	-	-	
138	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	0	0	-		-	-	-	-	-	-	-	
139	Zydus Lifesciences Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	1	3	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
140	Zydus Lifesciences Limited	Oneiro Chemicals Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	113	173	-		-	-	-	-	-	-	-	
141	Zydus Lifesciences Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	10	62	-		-	-	-	-	-	-	-	
142	Zydus Lifesciences Limited	Aleta Hospitals LLP [Formerly known as Zydus Hospitals (Vadodara) LLP]	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	0	0	-		-	-	-	-	-	-	-	
143	Zydus Lifesciences Limited	Dr. Sharvil P. Patel	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	196	271	-		-	-	-	-	-	-	-	
144	Zydus Lifesciences Limited	Mr. Ganesh N. Nayak	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	82	-	-		-	-	-	-	-	-	-	
145	Zydus Lifesciences Limited	Mr. Nitin D. Parekh	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	3	-	-		-	-	-	-	-	-	-	
146	Zydus Lifesciences Limited	Mr. Dhaval N. Soni	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	0	-	-		-	-	-	-	-	-	-	
147	Zydus Lifesciences Limited	Dialforhealth Unity Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	3	3	-		-	-	-	-	-	-	-	
148	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	228	2,453	-		-	-	-	-	-	-	-	
149	Zydus Lifesciences Limited	Zydus International Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	12,582	13,076	-		-	-	-	-	-	-	-	
150	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	9,396	9,765	-		-	-	-	-	-	-	-	
151	Zydus Lifesciences Limited	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	10,250	10,652	-		-	-	-	-	-	-	-	
152	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	8,263	2,545	-		-	-	-	-	-	-	-	
153	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	242	-	-		-	-	-	-	-	-	-	
154	Zydus Lifesciences Limited	Zydus Wellness Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1	4	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
155	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1	13	-		-	-	-	-	-	-	-	
156	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	5	8	-		-	-	-	-	-	-	-	
157	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	74	20	-		-	-	-	-	-	-	-	
158	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	1	4	-		-	-	-	-	-	-	-	
159	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	295	608	-		-	-	-	-	-	-	-	
160	Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	14	-		-	-	-	-	-	-	-	
161	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	61,770	59,596	-		-	-	-	-	-	-	-	
162	Zydus Lifesciences Limited	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	16	-		-	-	-	-	-	-	-	
163	Zydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1,797	2,285	-		-	-	-	-	-	-	-	
164	Zydus Lifesciences Limited	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	17	55	-		-	-	-	-	-	-	-	
165	Zydus Lifesciences Limited	Zydus Healthcare Philippines Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	210	499	-		-	-	-	-	-	-	-	
166	Zydus Lifesciences Limited	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	702	316	-		-	-	-	-	-	-	-	
167	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1,012	1,333	-		-	-	-	-	-	-	-	
168	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1,371	1,638	-		-	-	-	-	-	-	-	
169	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1,791	2,253	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
170	Zydus Lifesciences Limited	Zydus France, SAS	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	893	1,377	-		-	-	-	-	-	-	-	
171	Zydus Lifesciences Limited	Etna Biotech S.R.L.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	76	103	-		-	-	-	-	-	-	-	
172	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	96	69	-		-	-	-	-	-	-	-	
173	Zydus Lifesciences Limited	Laboratorios Comib S.L.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	248	474	-		-	-	-	-	-	-	-	
174	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	409	240	-		-	-	-	-	-	-	-	
175	Zydus Lifesciences Limited	Zydus Takeda Healthcare Private Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	74	-		-	-	-	-	-	-	-	
176	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	8	7	-		-	-	-	-	-	-	-	
177	Zydus Healthcare Limited	Oneiro Chemicals Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		10	Amount as approved by the Audit Committee.			10	-	-	-		-	-	-	-	-	-	-	
178	Zydus Healthcare Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
179	Zydus Healthcare Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
180	Zydus Healthcare Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
181	Zydus Healthcare Limited	Mukesh M. Patel & Co., Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
														Amount in INR Million except stated otherwise								
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
182	Zydus Healthcare Limited	German Remedies Pharma Private Limited	Subsidiary Company	Sale of goods or services		57	Amount as approved by the Audit Committee.			57	-	-	-		-	-	-	-	-	-	-	
183	Zydus Healthcare Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Sale of goods or services		17	Amount as approved by the Audit Committee.			17	-	-	-		-	-	-	-	-	-	-	
184	Zydus Healthcare Limited	Ramanbhai Foundation	Enterprises significantly influenced by Directors and/ or their relatives	Sale of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-	
185	Zydus Healthcare Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of goods or services		8	Amount as approved by the Audit Committee.			8	-	-	-		-	-	-	-	-	-	-	
186	Zydus Healthcare Limited	Dr. Sharvil P. Patel	Key Managerial Personnel	Any other transaction	Director Sitting Fees	-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
187	Zydus Healthcare Limited	Mr. Nitin D. Parekh	Key Managerial Personnel	Any other transaction	Director Sitting Fees	-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
188	Zydus Healthcare Limited	Sterling Biotech Limited	Joint Ventures	Purchase of goods or services		3	Amount as approved by the Audit Committee.			3	-	-	-		-	-	-	-	-	-	-	
189	Zydus Healthcare Limited	Sterling Biotech Limited	Joint Ventures	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	2	-		-	-	-	-	-	-	-	
190	Zydus Healthcare Limited	Zydus Foundation	Subsidiary Company	Sale of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
191	Zydus Healthcare Limited	Zydus Foundation	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	0	0	-		-	-	-	-	-	-	-	
192	Zydus Healthcare Limited	Zydus Lifesciences Limited	Parent Company	Loan		-	N.A.			1,880	-	-	-		-	-	Loans	1 Month T Bill + 35 BPS	5 Year	Unsecured	Business Purpose	
193	Zydus Healthcare Limited	Zydus Lifesciences Limited	Parent Company	Loan		-	N.A.			5,000	-	-	-		-	-	Loans	1 Month T Bill + 55 BPS	5 Year	Unsecured	Business Purpose	
194	Zydus Healthcare Limited	Zydus Lifesciences Limited	Parent Company	Loan		-	N.A.			4,075	-	-	-		-	-	Loans	1 Month T Bill + 90 BPS	5 Year	Unsecured	Business Purpose	
195	Zydus Healthcare Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Loan		-	N.A.			1,650	-	-	-		-	-	Loans	6 Month T Bill + 55 BPS	6 Month	Unsecured	Business Purpose	
196	Zydus Healthcare Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Loan		-	N.A.			1,650	-	-	-		-	-	-	-	-	-	-	
197	Zydus Healthcare Limited	Recon Pharmaceuticals and Investments	Subsidiary Company	Any other transaction	Share of profit Received	-	N.A.			0	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
198	Zydus Healthcare Limited	Zydus Healthcare Limited Employees Group Gratuity Scheme	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.			6	-	-	-		-	-	-	-	-	-	-	
199	Zydus Healthcare Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	0	0	-		-	-	-	-	-	-	-	
200	Zydus Healthcare Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	1	1	-		-	-	-	-	-	-	-	
201	Zydus Healthcare Limited	Ramanbhai Foundation	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	0	0	-		-	-	-	-	-	-	-	
202	Zydus Healthcare Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	8	6	-		-	-	-	-	-	-	-	
203	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Purchase of goods or services		38	Amount as approved by the Audit Committee.			38	-	-	-		-	-	-	-	-	-	-	
204	Zydus Wellness Limited	Alidac UK Limited	Subsidiary Company	Sale of goods or services		14	Amount as approved by the Audit Committee.			14	-	-	-		-	-	-	-	-	-	-	
205	Zydus Wellness Limited	Mukesh M. Patel & Co., Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-	
206	Zydus Wellness Limited	Zydus Healthcare Limited	Subsidiary Company	Loan		-	N.A.			350	-	-	-		-	-	-	-	-	-	-	
207	Zydus Wellness Limited	Zydus Healthcare Limited	Subsidiary Company	Interest paid		-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
208	Zydus Wellness Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.			-	358	-	-		-	-	-	-	-	-	-	
209	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of goods or services		1,596	Amount as approved by the Audit Committee.			1,596	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
														Amount in INR Million except stated otherwise								
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
210	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Sale of goods or services		32	Amount as approved by the Audit Committee.			32	-	-	-		-	-	-	-	-	-	-	
211	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of fixed assets		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
212	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of goods or services		208	Amount as approved by the Audit Committee.			208	-	-	-		-	-	-	-	-	-	-	
213	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Interest paid		-	N.A.			33	-	-	-		-	-	-	-	-	-	-	
214	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Loan		-	N.A.			560	-	-	-		-	-	-	-	-	-	-	
215	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Loan		-	N.A.			565	-	-	-		-	-	-	-	-	-	-	
216	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Loan		-	N.A.			450	-	-	-		-	-	-	-	-	-	-	
217	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	3	Amount as approved by the Audit Committee.			3	-	-	-		-	-	-	-	-	-	-	
218	Zydus Wellness Limited	Dr. Sharvil P. Patel	Key Managerial Personnel	Any other transaction	Director Sitting Fees	-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
219	Zydus Wellness Limited	Mr. Tarun Arora	Key Managerial Personnel	Remuneration		-	N.A.			7	-	-	-		-	-	-	-	-	-	-	
220	Zydus Wellness Limited	Mr. Umesh V. Parikh	Key Managerial Personnel	Remuneration		-	N.A.			15	-	-	-		-	-	-	-	-	-	-	
221	Zydus Wellness Limited	Mr. Nandish P. Joshi	Key Managerial Personnel	Remuneration		-	N.A.			1	-	-	-		-	-	-	-	-	-	-	
222	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Interest received		-	N.A.			9	-	-	-		-	-	-	-	-	-	-	
223	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Loan		-	N.A.			86	-	-	-		-	-	Loans	1 Year SOFR + 240 BPS	5 Year	Unsecured	Business Purpose	
224	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Loan		-	N.A.			52	-	-	-		-	-	Loans	1 Year SOFR + 210 BPS	5 Year	Unsecured	Business Purpose	
225	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Loan		-	N.A.			30	-	-	-		-	-	-	-	-	-	-	
226	Zydus Pharmaceuticals Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of fixed assets		-	N.A.			1,520	-	-	-		-	-	-	-	-	-	-	
227	Zydus Wellness Limited	Mr. Umesh V. Parikh	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	5	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
228	Naturell (India) Private Limited	Zydus Wellness Products Limited	Subsidiary Company	Purchase of goods or services		-	N.A.			4	-	-	-		-	-	-	-	-	-		
229	Naturell (India) Private Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of goods or services		-	N.A.			6	-	-	-		-	-	-	-	-	-		
230	Naturell (India) Private Limited	Zydus Wellness Products Limited	Subsidiary Company	Purchase of fixed assets		-	N.A.			1	-	-	-		-	-	-	-	-	-		
231	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	243	359	-		-	-	-	-	-	-		
232	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	44	55	-		-	-	-	-	-	-		
233	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.			-	440	1,133	-		-	-	-	-	-	-		
234	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	35	45	-		-	-	-	-	-	-		
235	Zydus Wellness Products Limited	Zydus Healthcare Limited	Subsidiary Company	Purchase of goods or services		-	N.A.			3	-	-	-		-	-	-	-	-	-		
236	Zydus Wellness Products Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of fixed assets		-	N.A.			0	-	-	-		-	-	-	-	-	-		
237	Zydus Wellness Products Limited	Mukesh M. Patel & Co., Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			1	-	-	-		-	-	-	-	-	-		
238	Zydus Wellness Products Limited	Mr. Tarun Arora	Key Managerial Personnel	Remuneration		-	N.A.			37	-	-	-		-	-	-	-	-	-		
239	Zydus Wellness Products Limited	Zydus Wellness International DMCC	Subsidiary Company	Sale of goods or services		-	N.A.			139	-	-	-		-	-	-	-	-	-		
240	Zydus Wellness Products Limited	Zydus Healthcare Limited	Subsidiary Company	Sale of goods or services		-	N.A.			39	-	-	-		-	-	-	-	-	-		
241	Zydus Wellness Products Limited	Zydus Wellness International DMCC	Subsidiary Company	Sale of goods or services		-	N.A.			3	-	-	-		-	-	-	-	-	-		
242	Zydus Wellness Products Limited	Zydus Healthcare Limited	Subsidiary Company	Sale of goods or services		-	N.A.			11	-	-	-		-	-	-	-	-	-		
243	Zydus Wellness Products Limited	Zydus Wellness International DMCC	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			10	-	-	-		-	-	-	-	-	-		
244	Zydus Wellness Products Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Sale of goods or services		-	N.A.			0	-	-	-		-	-	-	-	-	-		
245	Zydus Wellness Products Limited	LM Manufacturing India Private Limited	Subsidiary Company	Sale of goods or services		-	N.A.			2	-	-	-		-	-	-	-	-	-		
246	Zydus Wellness Products Limited	LM Manufacturing India Private Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			0	-	-	-		-	-	-	-	-	-		
247	Zydus Wellness Products Limited	LM Manufacturing India Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	0	0	-		-	-	-	-	-	-		

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
248	Zydus Wellness Products Limited	Heinz India Private Limited Pension Fund	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.			2	-	-	-		-	-	-	-	-	-	-	
249	Zydus Wellness Products Limited	Zydus Wellness Sikkim Employees Group Gratuity Scheme	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.			16	-	-	-		-	-	-	-	-	-	-	
250	Zydus Wellness Products Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
251	Zydus Wellness Products Limited	Zydus Wellness International DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	214	176	-		-	-	-	-	-	-	-	
252	Zydus Wellness Products Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	20	17	-		-	-	-	-	-	-	-	
253	German Remedies Pharma Private Limited	Zydus Healthcare Limited	Subsidiary Company	Sale of goods or services		-	N.A.			152	-	-	-		-	-	-	-	-	-	-	
254	German Remedies Pharma Private Limited	Zydus Foundation	Subsidiary Company	Sale of goods or services		-	N.A.			2	-	-	-		-	-	-	-	-	-	-	
255	German Remedies Pharma Private Limited	Zydus Foundation	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	1	-		-	-	-	-	-	-	-	
256	German Remedies Pharma Private Limited	Zydus Lifesciences Limited	Parent Company	Loan		-	N.A.			1,000	-	-	-		-	-	Loans	1 Month T Bill + 150 BPS	5 Year	Unsecured	Business Purpose	
257	German Remedies Pharma Private Limited	Recon Pharmaceuticals and Investments	Subsidiary Company	Any other transaction	Share of profit Received	-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
258	German Remedies Pharma Private Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	3	18	-		-	-	-	-	-	-	-	
259	Zydus Pharmaceuticals Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			22	-	-	-		-	-	-	-	-	-	-	
260	Zydus Pharmaceuticals Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Purchase of goods or services		-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
261	Zydus Pharmaceuticals Limited	Zydus Lifesciences Global FZE (UAE)	Subsidiary Company	Sale of goods or services		-	N.A.			4	-	-	-		-	-	-	-	-	-	-	
262	Zydus Pharmaceuticals Limited	Vitely Corp Pvt Ltd (Formerly Known Vitely Bio LLP)	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			1	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
263	Zydus Pharmaceuticals Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	5	9	-		-	-	-	-	-	-	-	
264	Zydus Pharmaceuticals Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	15	4	-		-	-	-	-	-	-	-	
265	Zydus Animal Health and Investments Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			1	-	-	-		-	-	-	-	-	-	-	
266	Zydus Animal Health and Investments Limited	Dialforhealth Unity Limited	Subsidiary Company	Interest received		-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
267	Zydus Animal Health and Investments Limited	Dialforhealth Unity Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	0	0	-		-	-	-	-	-	-	-	
268	Zydus Animal Health and Investments Limited	Sterling Biotech Limited	Joint Ventures	Investment		-	N.A.			-	6,708	-	-		-	-	-	-	-	-	-	
269	Zydus Animal Health and Investments Limited	Biochem Pharmaceutical Private Limited	Subsidiary Company	Investment		-	N.A.			1	-	1	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose	
270	Zydus Animal Health and Investments Limited	Zydus Medtech Private Limited	Subsidiary Company	Interest received		-	N.A.			45	-	-	-		-	-	-	-	-	-	-	
271	Zydus Animal Health and Investments Limited	Zydus Medtech Private Limited	Subsidiary Company	Loan		-	N.A.			988	-	-	-		-	-	Loans	1 Month T Bill + 120 BPS	5 Year	Unsecured	Business Purpose	
272	Zydus Animal Health and Investments Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			6	-	-	-		-	-	-	-	-	-	-	
273	Zydus Animal Health and Investments Limited	ZyVet Animal Health Inc	Subsidiary Company	Sale of goods or services		-	N.A.			507	-	-	-		-	-	-	-	-	-	-	
274	Zydus Animal Health and Investments Limited	Viona Pharmaceuticals INC	Subsidiary Company	Interest received		-	N.A.			11	-	-	-		-	-	-	-	-	-	-	
275	Zydus Animal Health and Investments Limited	Zydus Lifesciences Limited	Parent Company	Loan		-	N.A.			7,498	-	-	-		-	-	Loans	1 Month T Bill + 120 BPS	5 Year	Unsecured	Business Purpose	
276	Zydus Animal Health and Investments Limited	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	173	403	-		-	-	-	-	-	-	-	
277	Zydus Animal Health and Investments Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
278	Zydus Animal Health and Investments Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	0	0	-		-	-	-	-	-	-	-	
279	Zydus Animal Health and Investments Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	2	3	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
280	Zydus Animal Health and Investments Limited	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	427	444	-		-	-	-	-	-	-	-	
281	Zydus Animal Health and Investments Limited	Zydus Medtech Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	1,033	2,036	-		-	-	-	-	-	-	-	
282	Zydus Animal Health and Investments Limited	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	860	428	-		-	-	-	-	-	-	-	
283	Zydus Pharmaceuticals (USA) Inc.	NAI Laboratories Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			26	-	-	-		-	-	-	-	-	-	-	
284	Zydus Pharmaceuticals (USA) Inc.	Navinta III, Inc	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			111	-	-	-		-	-	-	-	-	-	-	
285	Zydus Pharmaceuticals (USA) Inc.	Navinta LLC	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			247	-	-	-		-	-	-	-	-	-	-	
286	Zydus Pharmaceuticals (USA) Inc.	Navinta NV, Inc.	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			223	-	-	-		-	-	-	-	-	-	-	
287	Zydus Pharmaceuticals (USA) Inc.	Zydus Healthcare (USA) LLC	Subsidiary Company	Loan		-	N.A.			294	-	-	-		-	-	-	-	-	-	-	
288	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Sale of goods or services		-	N.A.			3	-	-	-		-	-	-	-	-	-	-	
289	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Sale of goods or services		-	N.A.			3	-	-	-		-	-	-	-	-	-	-	
290	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Sale of goods or services		-	N.A.			3	-	-	-		-	-	-	-	-	-	-	
291	Zydus Pharmaceuticals (USA) Inc.	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Purchase of goods or services		-	N.A.			4,079	-	-	-		-	-	-	-	-	-	-	
292	Zydus Pharmaceuticals (USA) Inc.	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			1,185	-	-	-		-	-	-	-	-	-	-	
293	Zydus Pharmaceuticals (USA) Inc.	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	79	-		-	-	-	-	-	-	-	
294	Zydus Pharmaceuticals (USA) Inc.	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	4,357	5,109	-		-	-	-	-	-	-	-	
295	Zydus Pharmaceuticals (USA) Inc.	Zydus Healthcare (USA) LLC	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			0	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
296	Zydus Pharmaceuticals (USA) Inc.	Navinta LLC	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Reimbursement of Expenses paid	-	N.A.			12	-	-	-		-	-	-	-	-	-	-	
297	Zydus Pharmaceuticals (USA) Inc.	Navinta LLC	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			1	-	-	-		-	-	-	-	-	-	-	
298	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			1	-	-	-		-	-	-	-	-	-	-	
299	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			1	-	-	-		-	-	-	-	-	-	-	
300	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
301	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
302	Zydus Pharmaceuticals (USA) Inc.	Zydus Healthcare (USA) LLC	Subsidiary Company	Loan		-	N.A.			78	-	-	-		-	-	Loans	6 Month SOFR + 50 BPS	1 Year	Unsecured	Business Purpose	
303	Zydus Pharmaceuticals (USA) Inc.	Zydus Healthcare (USA) LLC	Subsidiary Company	Interest received		-	N.A.			6	-	-	-		-	-	-	-	-	-	-	
304	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Interest received		-	N.A.			66	-	-	-		-	-	-	-	-	-	-	
305	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Interest received		-	N.A.			25	-	-	-		-	-	-	-	-	-	-	
306	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Interest received		-	N.A.			12	-	-	-		-	-	-	-	-	-	-	
307	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Interest received		-	N.A.			214	-	-	-		-	-	-	-	-	-	-	
308	Zydus Pharmaceuticals (USA) Inc.	Zydus Pharmaceuticals Canada Inc.	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
309	Zydus Pharmaceuticals (USA) Inc.	Zydus Pharmaceuticals Canada Inc.	Subsidiary Company	Interest received		-	N.A.			2	-	-	-		-	-	-	-	-	-	-	
310	Zydus Pharmaceuticals (USA) Inc.	Zydus Pharmaceuticals Canada Inc.	Subsidiary Company	Loan		-	N.A.			43	-	-	-		-	-	Loans	3 Month SOFR + 50 BPS	1 Year	Unsecured	Business Purpose	
311	Zydus Pharmaceuticals (USA) Inc.	Zydus Pharmaceuticals Canada Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	51	98	-		-	-	-	-	-	-	-	
312	Zydus Pharmaceuticals (USA) Inc.	Zydus Pharmaceuticals Canada Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1	1	-		-	-	-	-	-	-	-	
313	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Loan		-	N.A.			210	-	-	-		-	-	Loans	6 Month SOFR + 50 BPS	1 Year	Unsecured	Business Purpose	
314	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Loan		-	N.A.			199	-	-	-		-	-	Loans	6 Month SOFR + 50 BPS	1 Year	Unsecured	Business Purpose	
315	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Loan		-	N.A.			1,475	-	-	-		-	-	Loans	6 Month SOFR + 50 BPS	1 Year	Unsecured	Business Purpose	
316	Zydus Pharmaceuticals (USA) Inc.	NAI Laboratories Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	16	27	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
317	Zydus Pharmaceuticals (USA) Inc.	Navinta III, Inc	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	0	75	-		-	-	-	-	-	-		
318	Zydus Pharmaceuticals (USA) Inc.	Navinta LLC	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	46	133	-		-	-	-	-	-	-		
319	Zydus Pharmaceuticals (USA) Inc.	Navinta NV, Inc.	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	89	99	-		-	-	-	-	-	-		
320	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	2,765	2,876	-		-	-	-	-	-	-		
321	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	941	1,193	-		-	-	-	-	-	-		
322	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	368	586	-		-	-	-	-	-	-		
323	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	8,120	9,949	-		-	-	-	-	-	-		
324	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	33	2	-		-	-	-	-	-	-		
325	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	8	7	-		-	-	-	-	-	-		
326	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	4	4	-		-	-	-	-	-	-		
327	Zydus Pharmaceuticals (USA) Inc.	Zylidac Bio LLC, USA	Subsidiary Company	Loan		-	N.A.			1	-	-	-		-	-	Loans	6 Month SOFR + 50 BPS	1 Year	Unsecured	Business Purpose	
328	Zydus Pharmaceuticals (USA) Inc.	Zylidac Bio LLC, USA	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	-	1	-		-	-	-	-	-	-		
329	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	33	39	-		-	-	-	-	-	-		
330	Zydus Worldwide DMCC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	-	N.A.			174	-	-	-		-	-	-	-	-	-		
331	Zydus Worldwide DMCC	Zydus Healthcare (USA) LLC	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	-	N.A.			1	-	-	-		-	-	-	-	-	-		
332	Zydus Worldwide DMCC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Sale of goods or services		-	N.A.			1,076	-	-	-		-	-	-	-	-	-		
333	Zydus Worldwide DMCC	Zydus Netherlands B.V.	Subsidiary Company	Interest received		-	N.A.			23	-	-	-		-	-	-	-	-	-		
334	Zydus Worldwide DMCC	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Interest received		-	N.A.			13	-	-	-		-	-	-	-	-	-		

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
													Amount in INR Million except stated otherwise									
													Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.									
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
335	Zydus Worldwide DMCC	Zydus Netherlands B.V.	Subsidiary Company	Investment		-	N.A.			10	-	10	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose	
336	Zydus Worldwide DMCC	Zydus France, SAS	Subsidiary Company	Interest received		-	N.A.			5	-	-	-		-	-	-	-	-	-	-	
337	Zydus Worldwide DMCC	Zydus France, SAS	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	216	228	-		-	-	-	-	-	-	-	
338	Zydus Worldwide DMCC	Zydus International Private Limited	Subsidiary Company	Interest received		-	N.A.			125	-	-	-		-	-	-	-	-	-	-	
339	Zydus Worldwide DMCC	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	553	587	-		-	-	-	-	-	-	-	
340	Zydus Worldwide DMCC	Zydus Netherlands B.V.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	982	1,044	-		-	-	-	-	-	-	-	
341	Zydus Worldwide DMCC	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	0	-		-	-	-	-	-	-	-	
342	Zydus Worldwide DMCC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	288	179	-		-	-	-	-	-	-	-	
343	Zydus Worldwide DMCC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	797	-		-	-	-	-	-	-	-	
344	Viona Pharmaceuticals INC	Zydus Pharmaceuticals Canada Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	0	-	-		-	-	-	-	-	-	-	
345	Viona Pharmaceuticals INC	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	0	-	-		-	-	-	-	-	-	-	
346	Zydus Healthcare (USA) LLC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Sale of goods or services		-	N.A.			19	-	-	-		-	-	-	-	-	-	-	
347	Zydus Healthcare (USA) LLC	Zydus Therapeutics INC	Subsidiary Company	Sale of goods or services		-	N.A.			3	-	-	-		-	-	-	-	-	-	-	
348	Zydus Healthcare (USA) LLC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	3	-		-	-	-	-	-	-	-	
349	Zydus Healthcare (USA) LLC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.			-	214	-	-		-	-	-	-	-	-	-	
350	Zydus Healthcare (USA) LLC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	1	0	-		-	-	-	-	-	-	-	
351	Zydus Healthcare (USA) LLC	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	0	-		-	-	-	-	-	-	-	
352	Zydus Healthcare (USA) LLC	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	0	2	-		-	-	-	-	-	-	-	
353	ZyVet Animal Health Inc	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			218	-	-	-		-	-	-	-	-	-	-	
354	Zydus Wellness International DMCC	Zydus Worldwide DMCC	Subsidiary Company	Purchase of goods or services		-	N.A.			1	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments				Details of loans/ investments					
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
355	Zydus Wellness International DMCC	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	1	1	-		-	-	-	-	-	-	-	
356	Zydus International Private Limited	RIC Chemicals LTD	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			2	-	-	-		-	-	-	-	-	-	-	
357	Zydus International Private Limited	Zydus Netherlands B.V.	Subsidiary Company	Interest received		-	N.A.			5	-	-	-		-	-	-	-	-	-	-	
358	Zydus International Private Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Interest received		-	N.A.			5	-	-	-		-	-	-	-	-	-	-	
359	Zydus International Private Limited	Zydus France, SAS	Subsidiary Company	Interest received		-	N.A.			7	-	-	-		-	-	-	-	-	-	-	
360	Zydus International Private Limited	Laboratorios Combix S.L.	Subsidiary Company	Interest received		-	N.A.			5	-	-	-		-	-	-	-	-	-	-	
361	Zydus International Private Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Loan		-	N.A.			5,499	-	-	-		-	-	-	-	-	-	-	
362	Zydus International Private Limited	Zydus Worldwide DMCC	Subsidiary Company	Loan		-	N.A.			5,186	-	-	-		-	-	-	-	-	-	-	
363	Zydus International Private Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Interest received		-	N.A.			22	-	-	-		-	-	-	-	-	-	-	
364	Zydus International Private Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	5,421	-	-		-	-	-	-	-	-	-	
365	Zydus International Private Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Interest received		-	N.A.			424	-	-	-		-	-	-	-	-	-	-	
366	Zydus International Private Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	17,115	18,220	-		-	-	-	-	-	-	-	
367	Zydus International Private Limited	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.			-	5,417	427	-		-	-	-	-	-	-	-	
368	Zydus International Private Limited	Zydus Netherlands B.V.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	256	294	-		-	-	-	-	-	-	-	
369	Zydus International Private Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	368	419	-		-	-	-	-	-	-	-	
370	Zydus International Private Limited	Zydus France, SAS	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	455	503	-		-	-	-	-	-	-	-	
371	Zydus International Private Limited	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	338	385	-		-	-	-	-	-	-	-	
372	Zydus France, SAS	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
373	Zydus France, SAS	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	0	0	-		-	-	-	-	-	-	-	
374	Zydus Healthcare S.A. (Pty) Ltd	Alidac Pharmaceuticals SA (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	421	466	-		-	-	-	-	-	-	-	
375	Zydus Healthcare S.A. (Pty) Ltd	Alidac Pharmaceuticals SA (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	51	57	-		-	-	-	-	-	-	-	
376	Script Management Services (Pty) Ltd	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Sale of goods or services		-	N.A.			450	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
377	Script Management Services (Pty) Ltd	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			0	-	-	-		-	-	-	-	-	-		
378	Script Management Services (Pty) Ltd	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	7	15	-		-	-	-	-	-	-		
379	Zydus Pharmaceuticals Mexico SA De CV	Zydus Pharmaceuticals Mexico Services Company SA De C.V.	Subsidiary Company	Purchase of goods or services		-	N.A.			0	-	-	-		-	-	-	-	-	-		
380	Zydus Healthcare Philippines Inc.	RJ Conception Law Office	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			0	-	-	-		-	-	-	-	-	-		
381	Alidac Healthcare (Myanmar) Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			1	-	-	-		-	-	-	-	-	-		
382	Alidac Healthcare (Myanmar) Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1	-	-		-	-	-	-	-	-		
383	Zynext Ventures Pte. Ltd.	Zynext Ventures USA LLC	Subsidiary Company	Investment		-	N.A.			-	781	-	-		-	-	-	-	-	-		
384	Zydus Pharmaceuticals UK Ltd.	LiqMeds Limited	Subsidiary Company	Interest received		-	N.A.			26	-	-	-		-	-	-	-	-	-		
385	Zydus Pharmaceuticals UK Ltd.	LM Manufacturing Limited	Subsidiary Company	Interest received		-	N.A.			48	-	-	-		-	-	-	-	-	-		
386	Zydus Pharmaceuticals UK Ltd.	Zydus France, SAS	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	1	-	-		-	-	-	-	-	-		
387	Zydus Pharmaceuticals UK Ltd.	LM Manufacturing Limited	Subsidiary Company	Loan		-	N.A.			905	-	-	-		-	-	-	-	-	-		
388	Zydus Pharmaceuticals UK Ltd.	LM Manufacturing Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	9	64	-		-	-	-	-	-	-		
389	Zydus Pharmaceuticals UK Ltd.	LM Manufacturing Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	1,704	911	-		-	-	-	-	-	-		
390	Zydus Pharmaceuticals UK Ltd.	LiqMeds Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	769	856	-		-	-	-	-	-	-		
391	Zydus Lifesciences Global FZE [UAE]	Zydus Lifesciences Limited	Parent Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	3,084	5,054	-		-	-	-	-	-	-		
392	Zydus Lifesciences Global FZE [UAE]	Viona Pharmaceuticals INC	Subsidiary Company	Sale of goods or services		-	N.A.			314	-	-	-		-	-	-	-	-	-		
393	Zydus Lifesciences Global FZE [UAE]	Zydus Healthcare (USA) LLC	Subsidiary Company	Purchase of goods or services		-	N.A.			13	-	-	-		-	-	-	-	-	-		
394	Zydus Lifesciences Global FZE [UAE]	Zydus Healthcare (USA) LLC	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	-	N.A.			8	-	-	-		-	-	-	-	-	-		

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
395	Zydus Lifesciences Global FZE [UAE]	Zydus Healthcare (USA) LLC	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	1	22	-		-	-	-	-	-	-	-	
396	Zydus Lifesciences Global FZE [UAE]	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	166	267	-		-	-	-	-	-	-	-	
397	LM Manufacturing Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			31	-	-	-		-	-	-	-	-	-	-	
398	LM Manufacturing Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Sale of goods or services		-	N.A.			15	-	-	-		-	-	-	-	-	-	-	
399	LiqMeds Worldwide Limited	LM Manufacturing Limited	Subsidiary Company	Sale of goods or services		-	N.A.			2	-	-	-		-	-	-	-	-	-	-	
400	LiqMeds Worldwide Limited	LiqMeds Lifecare Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	0	20	-		-	-	-	-	-	-	-	
401	LiqMeds Worldwide Limited	LiqMeds Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	18	44	-		-	-	-	-	-	-	-	
402	LM Manufacturing Limited	Oncosol Limited	Joint Ventures	Purchase of goods or services		-	N.A.			8	-	-	-		-	-	-	-	-	-	-	
403	LM Manufacturing Limited	Oncosol Limited	Joint Ventures	Sale of goods or services		-	N.A.			1	-	-	-		-	-	-	-	-	-	-	
404	LiqMeds Lifecare Limited	Oncosol Limited	Joint Ventures	Sale of goods or services		-	N.A.			3	-	-	-		-	-	-	-	-	-	-	
405	LM Manufacturing India Private Limited	LM Manufacturing Limited	Subsidiary Company	Sale of goods or services		-	N.A.			36	-	-	-		-	-	-	-	-	-	-	
406	LiqMeds Worldwide Limited	LM Manufacturing Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	937	2,400	-		-	-	-	-	-	-	-	
407	LiqMeds Worldwide Limited	Oncosol Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	0	0	-		-	-	-	-	-	-	-	
408	LM Manufacturing Limited	Medsolutions (Europe) Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	2	2	-		-	-	-	-	-	-	-	
409	LM Manufacturing Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	9	-	-		-	-	-	-	-	-	-	
410	LM Manufacturing Limited	Oncosol Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	8	2	-		-	-	-	-	-	-	-	
411	LiqMeds Limited	LM Manufacturing Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	340	485	-		-	-	-	-	-	-	-	
412	LiqMeds Lifecare Limited	LM Manufacturing Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	37	38	-		-	-	-	-	-	-	-	
413	LM Manufacturing India Private Limited	LM Manufacturing Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	13	9	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
													Amount in INR Million except stated otherwise									
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
414	LiqMeds Lifecare Limited	LiqMeds Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1	1	-		-	-	-	-	-	-	-	
415	LiqMeds Lifecare Limited	Medsolutions (Europe) Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	10	11	-		-	-	-	-	-	-	-	
416	LiqMeds Lifecare Limited	Oncosol Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	117	117	-		-	-	-	-	-	-	-	
417	Medsolutions (Europe) Limited	LiqMeds Worldwide Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	13	14	-		-	-	-	-	-	-	-	
418	Medsolutions (Europe) Limited	Oncosol Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	0	1	-		-	-	-	-	-	-	-	
419	Zydus Medtech Private Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of fixed assets		-	N.A.			1,037	-	-	-		-	-	-	-	-	-	-	
420	Zydus Medtech Private Limited	Zydus Medtech France SAS	Subsidiary Company	Investment		-	N.A.			202	0	202	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose	
421	Zydus Medtech Private Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
422	Zydus Worldwide DMCC	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	-	N.A.			4	-	-	-		-	-	-	-	-	-	-	
423	Zydus Worldwide DMCC	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1,249	-	-		-	-	-	-	-	-	-	
424	Zydus Healthcare S.A. (Pty) Ltd	DI Consultancy	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			12	-	-	-		-	-	-	-	-	-	-	
425	Zydus Medtech France SAS	Amplitude Surgical SAS	Subsidiary Company	Loan		-	N.A.			7,276	-	-	-		-	-	Loans	3 Month EURIBOR + 150 BPS	7 Year	Unsecured	Business Purpose	
426	Zydus Medtech France SAS	Amplitude Surgical SAS	Subsidiary Company	Interest received		-	N.A.			44	-	-	-		-	-	-	-	-	-	-	
427	Zydus Medtech France SAS	Amplitude Surgical SAS	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	-	7,606	-		-	-	-	-	-	-	-	
428	Zydus Medtech France SAS	Amplitude SAS [France]	Subsidiary Company	Loan		-	N.A.			1,321	-	-	-		-	-	Loans	3 Month EURIBOR + 150 BPS	7 Year	Unsecured	Business Purpose	
429	Zydus Medtech France SAS	Amplitude SAS [France]	Subsidiary Company	Interest received		-	N.A.			8	-	-	-		-	-	-	-	-	-	-	
430	Zydus Medtech France SAS	Amplitude SAS [France]	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	-	1,381	-		-	-	-	-	-	-	-	
431	Amplitude SAS [France]	SCI Les Tilleuls [France]	Subsidiary Company	Purchase of goods or services		-	N.A.			20	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																					
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																					
												Amount in INR Million except stated otherwise									
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.									
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments				Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
432	Amplitude SAS [France]	SCI SOFAB FALLA [France]	Subsidiary Company	Purchase of goods or services		-	N.A.			9	-	-	-		-	-	-	-	-	-	
433	Amplitude SAS [France]	Amplitude Ile de France [France]	Subsidiary Company	Purchase of goods or services		-	N.A.			33	-	-	-		-	-	-	-	-	-	
434	Amplitude SAS [France]	Duotech Amplitude SAS [France]	Subsidiary Company	Purchase of goods or services		-	N.A.			15	-	-	-		-	-	-	-	-	-	
435	Amplitude SAS [France]	Amplitude Sud SAS [France]	Subsidiary Company	Purchase of goods or services		-	N.A.			24	-	-	-		-	-	-	-	-	-	
436	Amplitude SAS [France]	Amplitude Nord SAS [France]	Subsidiary Company	Purchase of goods or services		-	N.A.			26	-	-	-		-	-	-	-	-	-	
437	Amplitude SAS [France]	Ortho Santé (Amplitude Ouest) [France]	Subsidiary Company	Purchase of goods or services		-	N.A.			30	-	-	-		-	-	-	-	-	-	
438	Amplitude SAS [France]	Amplitude Australia Pty Ltd [Australia]	Subsidiary Company	Sale of goods or services		-	N.A.			55	-	-	-		-	-	-	-	-	-	
439	Amplitude SAS [France]	Amplitude South Africa Pty Ltd [South Africa]	Subsidiary Company	Sale of goods or services		-	N.A.			11	-	-	-		-	-	-	-	-	-	
440	Amplitude SAS [France]	Amplitude Latin America SA [Brazil]	Subsidiary Company	Sale of goods or services		-	N.A.			21	-	-	-		-	-	-	-	-	-	
441	Amplitude SAS [France]	Amplitude Benelux [Belgium]	Subsidiary Company	Sale of goods or services		-	N.A.			35	-	-	-		-	-	-	-	-	-	
442	Amplitude SAS [France]	Amplitude Suisse SA [Switzerland]	Subsidiary Company	Sale of goods or services		-	N.A.			5	-	-	-		-	-	-	-	-	-	
443	Amplitude SAS [France]	Amplitude GmbH [Germany]	Subsidiary Company	Sale of goods or services		-	N.A.			5	-	-	-		-	-	-	-	-	-	
444	Amplitude SAS [France]	Amplitude Ile de France [France]	Subsidiary Company	Sale of goods or services		-	N.A.			2	-	-	-		-	-	-	-	-	-	
445	Amplitude SAS [France]	Amplitude Sud SAS [France]	Subsidiary Company	Sale of goods or services		-	N.A.			0	-	-	-		-	-	-	-	-	-	
446	Amplitude SAS [France]	Amplitude Nord SAS [France]	Subsidiary Company	Sale of goods or services		-	N.A.			0	-	-	-		-	-	-	-	-	-	
447	Amplitude SAS [France]	Ortho Santé (Amplitude Ouest) [France]	Subsidiary Company	Sale of goods or services		-	N.A.			0	-	-	-		-	-	-	-	-	-	
448	Amplitude SAS [France]	Amplitude Benelux [Belgium]	Subsidiary Company	Sale of goods or services		-	N.A.			6	-	-	-		-	-	-	-	-	-	
449	Amplitude SAS [France]	Amplitude Orthopedics Corporation [USA]	Subsidiary Company	Interest received		-	N.A.			2	-	-	-		-	-	-	-	-	-	
450	Amplitude SAS [France]	Amplitude Australia Pty Ltd [Australia]	Subsidiary Company	Interest received		-	N.A.			6	-	-	-		-	-	-	-	-	-	
451	Amplitude SAS [France]	Amplitude South Africa Pty Ltd [South Africa]	Subsidiary Company	Interest received		-	N.A.			2	-	-	-		-	-	-	-	-	-	
452	Amplitude SAS [France]	Amplitude Benelux [Belgium]	Subsidiary Company	Interest received		-	N.A.			1	-	-	-		-	-	-	-	-	-	
453	Amplitude SAS [France]	Amplitude Suisse SA [Switzerland]	Subsidiary Company	Interest received		-	N.A.			0	-	-	-		-	-	-	-	-	-	
454	Amplitude SAS [France]	Amplitude GmbH [Germany]	Subsidiary Company	Interest received		-	N.A.			0	-	-	-		-	-	-	-	-	-	
455	Amplitude SAS [France]	SCI Les Tilleuls [France]	Subsidiary Company	Interest paid		-	N.A.			1	-	-	-		-	-	-	-	-	-	
456	Amplitude SAS [France]	SCI SOFAB FALLA [France]	Subsidiary Company	Interest paid		-	N.A.			0	-	-	-		-	-	-	-	-	-	
457	Amplitude SAS [France]	Amplitude Ile de France [France]	Subsidiary Company	Interest paid		-	N.A.			0	-	-	-		-	-	-	-	-	-	
458	Amplitude SAS [France]	Duotech Amplitude SAS [France]	Subsidiary Company			-				0	-	-	-		-	-	-	-	-	-	
459	Amplitude SAS [France]	Amplitude Sud SAS [France]	Subsidiary Company			-				0	-	-	-		-	-	-	-	-	-	
460	Amplitude SAS [France]	Amplitude Nord SAS [France]	Subsidiary Company			-				0	-	-	-		-	-	-	-	-	-	
461	Amplitude SAS [France]	Ortho Santé (Amplitude Ouest) [France]	Subsidiary Company			-				0	-	-	-		-	-	-	-	-	-	
462	Amplitude SAS [France]	SCI Les Tilleuls [France]	Subsidiary Company			-				-	-	289	-		-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
463	Amplitude SAS [France]	SCI SOFAB FALLA [France]	Subsidiary Company			-				-	-	11	-		-	-	-	-	-	-	-	
464	Amplitude SAS [France]	Amplitude Ile de France [France]	Subsidiary Company			-				-	-	35	-		-	-	-	-	-	-	-	
465	Amplitude SAS [France]	Duotech Amplitude SAS [France]	Subsidiary Company			-				-	-	40	-		-	-	-	-	-	-	-	
466	Amplitude SAS [France]	Amplitude Sud SAS [France]	Subsidiary Company			-				-	-	79	-		-	-	-	-	-	-	-	
467	Amplitude SAS [France]	Amplitude Nord SAS [France]	Subsidiary Company			-				-	-	30	-		-	-	-	-	-	-	-	
468	Amplitude SAS [France]	Ortho Santé (Amplitude Ouest) [France]	Subsidiary Company			-				-	-	68	-		-	-	-	-	-	-	-	
469	Amplitude SAS [France]	Amplitude Latin America SA [Brazil]	Subsidiary Company			-				-	-	0	-		-	-	-	-	-	-	-	
470	Amplitude SAS [France]	SCI Les Tilleuls [France]	Subsidiary Company			-				-	-	14	-		-	-	-	-	-	-	-	
471	Amplitude SAS [France]	SCI SOFAB FALLA [France]	Subsidiary Company			-				-	-	4	-		-	-	-	-	-	-	-	
472	Amplitude SAS [France]	Amplitude Ile de France [France]	Subsidiary Company			-				-	-	41	-		-	-	-	-	-	-	-	
473	Amplitude SAS [France]	Duotech Amplitude SAS [France]	Subsidiary Company			-				-	-	19	-		-	-	-	-	-	-	-	
474	Amplitude SAS [France]	Amplitude Sud SAS [France]	Subsidiary Company			-				-	-	30	-		-	-	-	-	-	-	-	
475	Amplitude SAS [France]	Amplitude Nord SAS [France]	Subsidiary Company			-				-	-	34	-		-	-	-	-	-	-	-	
476	Amplitude SAS [France]	Ortho Santé (Amplitude Ouest) [France]	Subsidiary Company			-				-	-	38	-		-	-	-	-	-	-	-	
477	Amplitude SAS [France]	Amplitude Orthopedics Corporation [USA]	Subsidiary Company			-				-	-	638	-		-	-	-	-	-	-	-	
478	Amplitude SAS [France]	Amplitude Australia Pty Ltd [Australia]	Subsidiary Company			-				-	-	2,035	-		-	-	-	-	-	-	-	
479	Amplitude SAS [France]	Amplitude South Africa Pty Ltd [South Africa]	Subsidiary Company			-				-	-	492	-		-	-	-	-	-	-	-	
480	Amplitude SAS [France]	SCI Les Tilleuls [France]	Subsidiary Company			-				-	-	22	-		-	-	-	-	-	-	-	
481	Amplitude SAS [France]	Amplitude Benelux [Belgium]	Subsidiary Company			-				-	-	221	-		-	-	-	-	-	-	-	
482	Amplitude SAS [France]	Amplitude Suisse SA [Switzerland]	Subsidiary Company			-				-	-	137	-		-	-	-	-	-	-	-	
483	Amplitude SAS [France]	Amplitude GmbH [Germany]	Subsidiary Company			-				-	-	98	-		-	-	-	-	-	-	-	
484	Amplitude SAS [France]	Amplitude Australia Pty Ltd [Australia]	Subsidiary Company			-				-	-	99	-		-	-	-	-	-	-	-	
485	Amplitude SAS [France]	Amplitude South Africa Pty Ltd [South Africa]	Subsidiary Company			-				-	-	12	-		-	-	-	-	-	-	-	
486	Amplitude SAS [France]	Amplitude Latin America SA [Brazil]	Subsidiary Company			-				-	-	241	-		-	-	-	-	-	-	-	
487	Amplitude SAS [France]	Amplitude Ile de France [France]	Subsidiary Company			-				-	-	2	-		-	-	-	-	-	-	-	
488	Amplitude SAS [France]	Duotech Amplitude SAS [France]	Subsidiary Company			-				-	-	0	-		-	-	-	-	-	-	-	
489	Amplitude SAS [France]	Amplitude Sud SAS [France]	Subsidiary Company			-				-	-	1	-		-	-	-	-	-	-	-	
490	Amplitude SAS [France]	Amplitude Nord SAS [France]	Subsidiary Company			-				-	-	1	-		-	-	-	-	-	-	-	
491	Amplitude SAS [France]	Ortho Santé (Amplitude Ouest) [France]	Subsidiary Company			-				-	-	53	-		-	-	-	-	-	-	-	
492	Amplitude SAS [France]	Amplitude Benelux [Belgium]	Subsidiary Company			-				-	-	47	-		-	-	-	-	-	-	-	
493	Amplitude SAS [France]	Amplitude Suisse SA [Switzerland]	Subsidiary Company			-				-	-	5	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended September 30, 2025																						
													Amount in INR Million except stated otherwise									
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
494	Amplitude SAS [France]	Amplitude GmbH [Germany]	Subsidiary Company			-				-	-	1	-		-	-	-	-	-	-	-	
495	Amplitude Surgical SAS	Amplitude SAS [France]	Subsidiary Company			-				32	-	-	-		-	-	-	-	-	-	-	
496	Amplitude Surgical SAS	Amplitude SAS [France]	Subsidiary Company			-				17	-	-	-		-	-	-	-	-	-	-	
497	Amplitude Surgical SAS	SCI Les Tilleuls [France]	Subsidiary Company			-				1	-	-	-		-	-	-	-	-	-	-	
498	Amplitude Surgical SAS	Amplitude SAS [France]	Subsidiary Company			-				-	-	3,526	-		-	-	-	-	-	-	-	
499	Amplitude Surgical SAS	SCI Les Tilleuls [France]	Subsidiary Company			-				-	-	261	-		-	-	-	-	-	-	-	
500	Amplitude Ile de France [France]	Amplitude Sud SAS [France]	Subsidiary Company			-				0	-	-	-		-	-	-	-	-	-	-	
501	Amplitude Ile de France [France]	Duotech Amplitude SAS [France]	Subsidiary Company			-				0	-	-	-		-	-	-	-	-	-	-	
502	Amplitude Ile de France [France]	Amplitude Sud SAS [France]	Subsidiary Company			-				0	-	-	-		-	-	-	-	-	-	-	
503	Amplitude Ile de France [France]	Amplitude Nord SAS [France]	Subsidiary Company			-				0	-	-	-		-	-	-	-	-	-	-	
504	Amplitude Ile de France [France]	Amplitude Sud SAS [France]	Subsidiary Company			-				-	-	0	-		-	-	-	-	-	-	-	
505	Amplitude Ile de France [France]	Duotech Amplitude SAS [France]	Subsidiary Company			-				-	-	0	-		-	-	-	-	-	-	-	
506	Amplitude Ile de France [France]	Amplitude Sud SAS [France]	Subsidiary Company			-				-	-	0	-		-	-	-	-	-	-	-	
507	Amplitude Ile de France [France]	Amplitude Nord SAS [France]	Subsidiary Company			-				-	-	0	-		-	-	-	-	-	-	-	
508	Comfort Click Softech Pvt. Ltd.	Comfort Click Limited (UK)	Subsidiary Company			-				64	-	-	-		-	-	-	-	-	-	-	
509	Comfort Click Limited (UK)	Comfort Click Limited (Ireland)	Subsidiary Company			-				2	-	-	-		-	-	-	-	-	-	-	
510	Comfort Click Limited (UK)	Comfort Click Limited (Ireland)	Subsidiary Company			-				7	-	-	-		-	-	-	-	-	-	-	
511	Comfort Click Limited (UK)	Comfort Click Limited (Ireland)	Subsidiary Company			-				-	-	129	-		-	-	-	-	-	-	-	
512	Comfort Click Limited (UK)	Comfort Click Softech Pvt. Ltd.	Subsidiary Company			-				-	-	9	-		-	-	-	-	-	-	-	

Notes:

1 Amount mentioned as 0 denotes value less than INR 1 Million.

2 Opening and closing balance are not given where there was no transaction of investment during the half year ended September 30, 2025.

3 Receivables / Payables other than loans represents combined balance against sales / purchase pertaining to goods/ propoerty, plant and equipment / various services / reimbursement of expenses. Hence shown separately.